These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30445951)

  • 1. Safety profile of trifluridine/tipiracil monotherapy in clinical practice: results of the German compassionate-use program for patients with metastatic colorectal cancer.
    Kasper S; Kisro J; Fuchs M; Müller C; Schulz-Abelius A; Karthaus M; Rafiyan MR; Stein A
    BMC Cancer; 2018 Nov; 18(1):1124. PubMed ID: 30445951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
    Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
    Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
    Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
    Van Cutsem E; Hochster H; Shitara K; Mayer R; Ohtsu A; Falcone A; Yoshino T; Doi T; Ilson DH; Arkenau HT; George B; Benhadji KA; Makris L; Tabernero J
    ESMO Open; 2022 Dec; 7(6):100633. PubMed ID: 36455504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib.
    Patel AK; Barghout V; Yenikomshian MA; Germain G; Jacques P; Laliberté F; Duh MS
    Oncologist; 2020 Jan; 25(1):e75-e84. PubMed ID: 31591140
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Trifluridine/Tipiracil-Containing Combinations in Colorectal Cancer and Other Advanced Solid Tumors: A Systematic Review.
    Shitara K; Falcone A; Fakih MG; George B; Sundar R; Ranjan S; Van Cutsem E
    Oncologist; 2024 May; 29(5):e601-e615. PubMed ID: 38366864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
    Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
    Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of Trifluridine/Tipiracil Treatment for Elderly Patients With Metastatic Colorectal Cancer in a Real-world Setting.
    Shibutani M; En W; Okazaki Y; Kashiwagi S; Fukuoka T; Iseki Y; Hirakawa K; Ohira M
    Anticancer Res; 2021 Dec; 41(12):6211-6216. PubMed ID: 34848475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world use of trifluridine/tipiracil for patients with metastatic colorectal cancer in Canada.
    Samawi HH; Brezden-Masley C; Afzal AR; Cheung WY; Dolley A
    Curr Oncol; 2019 Oct; 26(5):319-329. PubMed ID: 31708650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regorafenib-to-trifluridine/tipiracil Versus the Reverse Sequence for Refractory Metastatic Colorectal Cancer Patients: A Multicenter Retrospective Real-life Experience.
    Signorelli C; Gemma D; Grande R; DE Marco S; Saltarelli R; Morandi MG; Spinelli GP; Zoratto F; Sperduti I; Chilelli MG; Ceribelli A; Ruggeri EM
    Anticancer Res; 2021 May; 41(5):2553-2561. PubMed ID: 33952483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, safety and quality of life of trifluridine/tipiracil in pretreated patients with metastatic colorectal cancer: Real-world data from the noninterventional TACTIC study in Germany.
    Kröning H; Göhler T; Decker T; Grundeis M; Kojouharoff G; Lipke J; Semsek D; Moorahrend E; Sauer A; Bruch HR; Liersch R; Nusch A; Vehling-Kaiser U; Welslau M; Grunewald R; Harich HD; Stephany M; Uhlig J; de Buhr R; Frank M; Hogrefe C; Marschner N; Potthoff K; Hartmann F; Reisländer T; Schwaner I
    Int J Cancer; 2023 Sep; 153(6):1227-1240. PubMed ID: 37260368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subgroup analyses from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial.
    Karthaus M; Heinemann V; Riera-Knorrenschild J; Kretzschmar A; Welslau M; Kaiser U; Pelz H; Ettrich TJ; Held S; Kehmann L; Hess J; Reisländer T; Weiss L;
    BMC Cancer; 2024 Jul; 24(1):887. PubMed ID: 39044160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appropriateness of trifluridine/tipiracil in the clinical practice of third-line therapy in metastatic colorectal cancer.
    Barone C; Bartolomeo MD; Lonardi S; Maiello E; Martinelli E; Moretto R; Strippoli A; Tamburini E; Zaniboni A; Pinto C
    Future Oncol; 2021 May; 17(14):1749-1759. PubMed ID: 33464133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.
    Saif MW; Becerra CR; Fakih MG; Sun W; Popovic L; Krishnamurthi S; George TJ; Rudek MA; Shepard DR; Skopek J; Sramek V; Zaric B; Yamamiya I; Benhadji KA; Hamada K; He Y; Rosen L
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):485-497. PubMed ID: 34097100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase 2 trial of trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable metastatic colorectal cancer.
    Patel MR; Falchook GS; Hamada K; Makris L; Bendell JC
    Cancer Med; 2021 Feb; 10(4):1183-1190. PubMed ID: 33544407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective Sequential Combined Chemotherapy with Trifluridine/Tipiracil and Regorafenib in Human Colorectal Cancer Cells.
    Matsuoka K; Nakagawa F; Tanaka N; Okabe H; Matsuo K; Takechi T
    Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30257515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel antimetabolite: TAS-102 for metastatic colorectal cancer.
    Miyamoto Y; Lenz HJ; Baba H
    Expert Rev Clin Pharmacol; 2016; 9(3):355-65. PubMed ID: 26677869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
    Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
    Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer.
    Prager GW; Taieb J; Fakih M; Ciardiello F; Van Cutsem E; Elez E; Cruz FM; Wyrwicz L; Stroyakovskiy D; Pápai Z; Poureau PG; Liposits G; Cremolini C; Bondarenko I; Modest DP; Benhadji KA; Amellal N; Leger C; Vidot L; Tabernero J;
    N Engl J Med; 2023 May; 388(18):1657-1667. PubMed ID: 37133585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of food on the pharmacokinetics of TAS-102 and its efficacy and safety in patients with advanced solid tumors.
    Yoshino T; Kojima T; Bando H; Yamazaki T; Naito Y; Mukai H; Fuse N; Goto K; Ito Y; Doi T; Ohtsu A
    Cancer Sci; 2016 May; 107(5):659-65. PubMed ID: 26918279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.